Aurora-B (06681): Dosage research results for cognitive digital therapy in children were published in “BMC Medicine”

Zhitong Finance App News, Brain Action Aurora-B (06681) issued an announcement. The Group has recently achieved important scientific research results in the field of dose research in cognitive digital therapy for children. The relevant information is now announced as follows:

Recently, the study “Optimal Therapeutics of Cognitive Digital Therapeutics for Pediatric Patients with Cognitive Disorders: A Retrospective Study Based on Big Data”, jointly conducted by Professor Ni Xin's team from Beijing Children's Hospital Affiliated to Capital Medical University and the research team of the Group, was published in the top international comprehensive Medical journal BMC Medicine (2025 Journal Impact Factor: 8.7).

The study is a retrospective study based on real world data. It included 38,526 cognitively impaired children and adolescents (3-18 years) who completed at least two weeks of training using the Group's “Brain Function Information Management Platform Software System” (Class II medical device, Xiang Device Note: 20182210142). The system depicts the dose-response relationship in the three dimensions of daily training time, weekly training frequency, and total training cycle. The platform includes 123 tasks adapted from classical paradigms, covering the four major cognitive areas of perception, attention, memory, and executive function. The study used the average cognitive index (MCI) as the main outcome index to reflect comprehensive task performance during training.

Key results:

(1) The optimal daily dose for the overall population: Using 0-4 minutes a day as the baseline, training for more than 8 minutes in a single day can there be a significant improvement. 16-20 minutes a day corresponds to the highest cognitive performance, making it the best daily dose for the overall population. After exceeding this range, continuing to train for a single day did not bring any significant additional benefits.

(ii) Age and gender stratification differences: The four subgroups showed different optimal daily doses and total doses:

(3) Weekly training frequency: The highest cognitive performance of the four subgroups all showed 7 days of weekly training; most subgroups required at least 5 days of weekly training to show significant improvement.

(4) Overall intervention cycle: Regardless of age and gender, children who have been trained for more than 1 month showed significant cognitive improvement compared to those who had been trained for less than 1 month.

According to the findings, this is the first large-scale study to define the optimal age and gender specific digital training dose for children with cognitive impairment, providing strong evidence for individualized cognitive digital therapy intervention and providing a reference for the formulation of future treatment guidelines.

Based on real-world data from 38,526 children, this study was the first to systematically define the optimal digital training dose for different ages and genders, filling the gap in research on dose-response relationships in the field of cognitive digital therapy for children, and providing an evidence-based basis for individualized and accurate intervention. The results were published in the top international comprehensive medical journal “BMC Medicine”, reflecting the Group's leading capabilities in large-scale real-world data research in cognitive digital therapy, and further expanding the Group's evidence-based evidence-based digital therapy landscape to cover diverse groups of people with cognitive impairment in children.

The Board of Directors believes that the above results are in line with the Group's long-term development strategy and will further consolidate the Group's leading position in the field of digital therapy for cognitive impairment and digital therapy for pediatric diseases, and create long-term value for shareholders.